Form 8-K - Current report:
SEC Accession No. 0001140361-24-044892
Filing Date
2024-11-01
Accepted
2024-11-01 09:24:24
Documents
14
Period of Report
2024-11-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20038055_8k.htm   iXBRL 8-K 36205
2 EXHIBIT 99.1 ef20038055_ex99-1.htm EX-99.1 15602
  Complete submission text file 0001140361-24-044892.txt   194139

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20241101.xsd EX-101.SCH 3979
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20241101_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20241101_pre.xml EX-101.PRE 16042
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20038055_8k_htm.xml XML 4227
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241417347
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)